Results 171 to 180 of about 98,202 (223)

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

The E3 ubiquitin ligase TRIM56 promotes aggregation and activation of Src protein through Lys63-linked polyubiquitination in hepatocellular carcinoma. [PDF]

Cell Death Dis
Zhu L, Cui X, Xu H, Yang M, Han L.
europepmc   +1 more source

Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients

International Journal of Cancer, Volume 158, Issue 3, Page 763-774, 1 February 2026.
What's new? Bladder cancer exhibits a highly heterogeneous molecular landscape and treatment response. The dysregulation of RNA modifications such as m6A has been involved in cancer initiation and progression. This study comprehensively analyzed the expression of the main catalytic component of the m6A methylation machinery in bladder tumors across one
Katerina‐Marina Pilala, Stella Koroneou, Maria‐Alexandra Papadimitriou, Konstantina Panoutsopoulou, Konstantinos Soureas, Georgios‐Christos Giagkos, Panagiotis Levis, Dimitrios Linardoutsos, Konstantinos Stravodimos, Margaritis Avgeris, Andreas Scorilas   +10 more
wiley   +1 more source

Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study. [PDF]

Mol Biomed
Shen YG, Ji MM, Shi Q, Wei XL, Fan L, Liu TB, Liu Y, Dong LH, Liang AB, Huang L, Zhou H, Huang HH, Yang SM, Wang XB, Tian YY, Zhu ZM, Bai O, Li F, Shi WY, Xu B, Wang X, Shi KQ, Tang W, Yi HM, Chen SY, Zheng Z, Cheng S, Xu PP, Zhao WL, Wang L.   +29 more
europepmc   +1 more source

A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy

Journal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
ABSTRACT Tumour development and progression are driven by intricate interactions among various cell types within the tumour microenvironment (TME). Targeting a single cell type often fails to eradicate cancer, highlighting the need for strategies to co‐target multiple cell types.
Zhiang Liu, Ying Chen, Yulin Cao, Yanchao Zhang, Yuanben Wang, Han Cheng, Junhui Tang, Haofei Hong, Yuyang Feng, Surui Yao, Zehua Bian, Yuan Yin, Kaisa Cui, Zhimeng Wu, Zhaohui Huang   +14 more
wiley   +1 more source

The Silence of the Lambdas: Hidden Complexities in the Evolution of Double-Hit Lymphomas. [PDF]

Blood Cancer Discov
Shevchenko G, Hodson DJ.
europepmc   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source

PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies. [PDF]

Cells
Krishan S, Koach J, Lim T, Yeo K, Cheong F, Luo JS, Massudi H, Gao X, Heangsarath S, Kueh AJ, Herold MJ, Cheung BB, Marshall GM.   +12 more
europepmc   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study. [PDF]

Ann Hematol
Lu B, Wang Y, Jin M, Zhang J, Xu X, Zeng Y, Zhao L, Wang H.   +7 more
europepmc   +1 more source